Please assess the completion status of the following clinical trial:

Trial Title: Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Active patient (presently receiving medical care for SCA) at the St. Jude Comprehensive Sickle Cell Center (SJCSCC) or an affiliate or alliance of St Jude. Patient must not be in the high risk category as defined by the SJCSCC. High risk is defined as follows:~* 3 or more admissions and/or emergency department visits for pain within the past 12 months, or;~* 2 or more episodes of acute chest syndrome within the past 24 months, or;~* A combination of pain and ACS events \> 3 within the past 12 months.~* 5-18 years of age~* Diagnosis of Hb SS or HB0Thal~* Weight \>15 kg~* \<50th percentile for height/age or weight/age or weight/ height, or \<90% ideal body weight, or \<90% of BMI for age/ gender.~* Is willing to sign informed consent~Exclusion Criteria~* Patients receiving hydroxyurea or any other anti-sickling agent, chronic transfusion, or nutrition supplements.A nutrition supplement is any high calorie or high protein food additive or oral supplement being used for the purpose of weight gain.~* History of poor compliance (Missing two or more clinic appointments in the past year).~* Renal or liver dysfunction~* Renal dysfunction as defined by serum creatinine \>1.5 times normal for age based on testing lab.~* Hepatic dysfunction as defined by alanine aminotransferase (ALT) \>2 times the upper limit of normal for age based on testing lab.~* Breastfeeding~* Pregnancy.Females of childbearing potential must have negative serum or urine pregnancy test (record date of test).~* Patients enrolled on previous glutamine protocol (SCDGLU).~* Patients who are considered high risk

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Glutamine
- 1 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).